On 6 September 2024, the Supreme Court of the Netherlands ruled in favour of Malaysia by dismissing an appeal filed by seven Filipino Citizens, the alleged heirs of the Sultanate of Sulu. The Filipino Citizens were seeking to overturn a Hague Court of Appeal decision dated 27 June 2023 which dismissed their application for recognition and enforcement in the Netherlands of a purported arbitral award amounting to USD 14,92 billion and rendered by Dr. Gonzalo Stampa against Malaysia. De Brauw successfully argued that the Hague Court of Appeal decision should be upheld. The Supreme Court judgment can be found here (in Dutch).

De Brauw advised G Square on the contemplated sale of its portfolio company, the Duomed Group to Palex Medical through execution of a put option agreement. The Duomed Group is a dynamic organization with a well-established reputation and is active in consultancy, sales, integration, training and technical support of medical technology and devices for hospitals and medical practices. The Duomed Group is active in Denmark, Sweden, The Netherlands, Belgium, Luxembourg, France, Switzerland, the UK, Serbia and Slovenia. The envisaged transaction would form a truly pan-European platform, providing medical technology equipment and solutions across Northern, Western, and Southern Europe

De Brauw is advising Aquiline Capital Partners on the sale of its stake in Quintes, one of the largest independent insurance brokers in the Netherlands, together with the other shareholders being Gijsbert van de Nieuwegiessen (founder) and key management, to Brown & Brown, Inc.

De Brauw advises Astorg in connection with the announcement of the successful closing of the Normec Continuation Fund, capitalized by lead investors CVC Secondary Partners, Pantheon, Lexington Partners, and Eurazeo, alongside a diverse group of additional investors, including sovereign wealth funds, pension funds, asset managers, and family offices.

De Brauw advised Parcom on its acquisition of RECO, a company specializing in rental equipment for the construction, infrastructure, and industrial sectors.

De Brauw advised General Atlantic’s BeyondNetZero climate growth fund on its majority investment in GRESB, a leading global provider of sustainability standards and benchmarks for real assets.

De Brauw advised SHV on the divestment of ERIKS to an affiliate of Lone Star.

De Brauw assisted Pon Holdings BV ("Pon") on its strategic partnership with Cooperative Resources International ("CRI") and CVC Capital Partners IX ("CVC") in URUS Group. URUS Group is a global leader in delivering products and services for dairy and beef artificial insemination genetics, reproduction, and farm management data systems. URUS companies service dairy and beef producers in more than 80 countries around the globe. As a market leader in dairy information management, the URUS cloud platform monitors over 14 million cows and heifers across 6,000 dairies. With their partnership, CVC, CRI and Pon intend to enable URUS Group to pursue the next phase of its ambitious growth plan, and further accelerate the development of its business and product portfolio for its members and clients. The transaction is expected to close in Q3 2024. De Brauw acted as counsel to Pon, advising on a range of topics including corporate, M&A, tax and competition.

De Brauw advised Delta Fiber on the sale of part of its optical fiber telecommunications network to Glaspoort, a joint venture of KPN and ABP. The transaction involves around 200.000 fiber-to-the-home consumer connections in sparsely populated areas across several regions in the Netherlands.

De Brauw advises Altaïr Group on the acquisition of Marcel's Green Soap.

De Brauw Blackstone Westbroek advises Qwello on the acquisition of 100% of the issued and outstanding shares in the capital in PARKnCHARGE.

De Brauw is assisting Heineken in invalidation proceedings before the General Court of the EU against AB Inbev in relation to the latter's EU trademark "ULTRA", registered for beer (Class 29). The EUIPO upheld the validity of the trademark, even though the EUIPO Guidelines and case law confirm that the sign at hand is a laudatory term commonly and lacks distinctive character. De Brauw appealed the EUIPO's judgment before the General Court of the EU.